DRTS Company Profile and Key Details

DRTS has shown sold momentum, gaining 29.49% over the past week and 55.21% over the past quarter, though year-to-date performance is up 29.49%. Short-term trend indicators are bearishly aligned (SMA20 31.19%, SMA50 55.28%, SMA200 95.87%). The stock’s 14-day RSI is 82.96 (overbought), while the ATR of 0.36 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 6.45% below its high and over 201.3% above its low. Average 10-day trading volume of 418.87 thousand shares is significantly above the 3-month average of 143.12 thousand, indicating heightened recent market interest.

Alpha Tau Medical Ltd. generated EPS of -$0.52 over the past year. Five-year average earnings growth is -19.9%. Wall Street analysts project EPS growth of 6.65% annually over the next five years. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.12. Next year's EPS is expected at -$30.65. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $8.00. The high target offers 29.87% upside. The low target suggests 15.44% downside. The mean target is $8.80. This offers 26.98% upside. Alpha Tau Medical Ltd. earnings surprise history is a mixed track record. The quarter that ended November 20, 2025, missed forecasts by -7.29%. The prior quarter beat by 8.33%. Over the last six quarters, Apple has recorded several small beats. These include -15.38% in May 20, 2024.

Alpha Tau Medical Ltd. has 85.04 million shares outstanding. The public float is 57.13 million shares, elevated short interest at 0.14% of float. This equals 91.11 thousand shares. The short ratio is 1.52 days. Institutional investors hold 3.39% of the float. Insiders own 32.79%.

Alpha Tau Medical Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading above this model’s fair value.

Alpha Tau Medical Ltd. (NASDAQ:DRTS) closed at $6.93 USD, gaining $0.52 (8.11%) from the previous close of $6.41. The stock is currently trading near its 52-week high $2.30 and $6.99. With a market capitalization of about $590.82 million, Alpha Tau Medical Ltd. is classified as a small-cap and shows market-like volatility (beta ~1.04). Key stats such as the average daily volume over the past year has been around 167.65 thousand shares, trading with heavier-than-usual volume. Headquartered in Jerusalem, None, Alpha Tau Medical Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Uzi Sofer, the company employs approximately 125 people and listed since March 08, 2021. Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.

Alpha Tau Medical Ltd. trades at a P/E ratio of -14.52, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.48 trading at moderately above to book value. The P/FCF stands at 0.0, also above market averages.

Our AI price prediction model suggests that Alpha Tau Medical Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.19%, with price expected at $7.29 by January 23, 2026, within a range of $6.91 to $7.68 3-Month Outlook: Projected rise of 16.88%, reaching $8.10 by April 09, 2026, with a range of $7.96 to $8.26. 1-Year Outlook: Projected gain of 373.3%, with price at $32.80 by December 31, 2026, within a range of $32.52 to $41.68.

Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares are up 29.49% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alpha Tau Medical Ltd. trading at a premium to the broader market with a P/E of -14.52. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.45, suggesting 50.79% upside. Our AI forecast model points to short-term strength (5.19% over two weeks), a medium-term rise (16.88% over three months), and a longer-term gain (373.3% over one year), with expected trading ranges indicating moderate volatility.